Şunu mu demek istediniz:
harm » arm (Aramayı Genişlet), farm (Aramayı Genişlet), hard (Aramayı Genişlet)
removeddss. » removedddss. (Aramayı Genişlet), remoteddss. (Aramayı Genişlet)
removesdddssdss. » removedsdddssdss. (Aramayı Genişlet), remotesdddssdss. (Aramayı Genişlet)
remove. » removed. (Aramayı Genişlet), remote. (Aramayı Genişlet)
resolve. » resolved. (Aramayı Genişlet)
harm » arm (Aramayı Genişlet), farm (Aramayı Genişlet), hard (Aramayı Genişlet)
removeddss. » removedddss. (Aramayı Genişlet), remoteddss. (Aramayı Genişlet)
removesdddssdss. » removedsdddssdss. (Aramayı Genişlet), remotesdddssdss. (Aramayı Genişlet)
remove. » removed. (Aramayı Genişlet), remote. (Aramayı Genişlet)
resolve. » resolved. (Aramayı Genişlet)
-
121
The degradation of PNP by <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crc</i>Y, and DLL-Δ<i>crcZ</i>.
Baskı/Yayın Bilgisi 2022Konular: -
122
The growth of <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crcY</i>, and DLL-Δ<i>crcZ</i> on LB medium.
Baskı/Yayın Bilgisi 2022Konular: -
123
Aggregated results for reported benefits and harms, stratified by leaflets and booklets.
Baskı/Yayın Bilgisi 2014“…<p>The figure indicates whether a leaflet contains <u>any</u> information on the benefits of CRC screening a) in general or specifically for b) colonoscopy or c) the FOBT, and whether it contains any information on the d) general and e) specific harms of colonoscopy. To be rated positive for harms, it was not sufficient if the only information about possible harms referred to pain, stating incorrectly that there is no pain involved.…”
-
124
-
125
Results of comparing visits within allergy groups using linear mixed models and post hoc analysis.
Baskı/Yayın Bilgisi 2025 -
126
Results of comparing allergy groups within visits using linear mixed models and post hoc analysis.
Baskı/Yayın Bilgisi 2025 -
127
-
128
Results of comparing treatment groups within visits using linear mixed models and post hoc analysis.
Baskı/Yayın Bilgisi 2025 -
129
-
130
Results of comparing visits within treatment groups using linear mixed models and post hoc analysis.
Baskı/Yayın Bilgisi 2025 -
131
-
132
-
133
-
134
Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB.
Baskı/Yayın Bilgisi 2025 -
135
-
136
-
137
-
138
Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB.
Baskı/Yayın Bilgisi 2025 -
139
Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study.
Baskı/Yayın Bilgisi 2025 -
140